Fig. 2From: Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysisScatter plot of incremental cost-effectiveness ratios (ICERs) generated from the probabilistic analysis (n = 10,000 iterations)Back to article page